Ask AI
ProCE Banner Activity

The Future Is Long Acting: HIV Prevention Insights for Canada From CROI

Clinical Thought

Although the overall incidence of new HIV infections in Canada remained stable throughout 2024, high rates of HIV acquisition persist in Manitoba and Saskatchewan, indicating a significant gap in PrEP uptake among vulnerable populations. Keep reading to learn how insights from CROI 2026 can help bridge this gap and reduce HIV transmission. 

Released: March 18, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions

Disclosure

Primary Author

Alexander Wong, MD, FRCPC: consultant/advisor/speaker: Gilead, Merck, ViiV.